HIF1A and prostate carcinoma: It has been shown that bortezomib inhibits HIF-1α transcriptional activity and attenuates its protein synthesis and the expression of its nuclear targets such as VEGF by inhibiting the PI3K/Akt/mTOR and MAPK pathways in AD and AI prostate cancer (PCa) cells, respectively [102].